Lonza Signs Manufacturing Agreement with Irish Firm

Lonza says it has entered into an agreement with drug development company Opsona Therapeutics (Dublin), for the production of the monoclonal antibody OPN-305, developed by Opsona. According to the agreement, Lonza will provide process development and cGMP manufacturing services for preclinical and Phase 1 studies using Lonza’s GS Gene Expression System. Financial details of the deal were not disclosed. Opsona, which was founded in 2004, is focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases. OPN-305 is a fully...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers